trial · primary record
Casdatifan
Metastatic Clear Cell Renal Cell Carcinoma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 720 |
| Primary completion | 2030-12 |
| Primary endpoint | Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 |
| Registry ID | NCT07011719 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:52.641Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07011719
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.